Stocklytics Platform
Asset logo for symbol NURO
NeuroMetrix
NURO55
$3.70arrow_drop_down0.26%-$0.01
Penny Stock
Asset logo for symbol NURO
NURO55

$3.70

arrow_drop_down0.26%

Performance History

Chart placeholder
Key Stats
Open$3.69
Prev. Close$3.71
EPS-6.30
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$7.15M
PE Ratio-
LOWHIGH
Day Range3.60
3.70
52 Week Range0.45
7.84
Ratios
EPS-6.30

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$805.15
Perf. (24h)
arrow_drop_down1.95%-$16.03
Market Cap$738.87B
Price$570.00
Perf. (24h)
arrow_drop_up1.84%$10.32
Market Cap$527.83B
Price$160.66
Perf. (24h)
arrow_drop_up0.63%$1.02
Market Cap$382.01B
Price$185.19
Perf. (24h)
arrow_drop_up1.65%$3.02
Market Cap$326.96B

About NeuroMetrix (NURO)

NeuroMetrix Inc (NURO) is a medical technology company specializing in the development and commercialization of products for the diagnosis and treatment of neurological disorders. With a focus on wearable devices and point-of-care diagnostics, NeuroMetrix is at the forefront of innovation in the healthcare industry. The company's flagship product, the Quell Wearable Pain Relief Device, is revolutionizing the management of chronic pain. Utilizing advanced neurostimulation technology, Quell provides widespread pain relief and improves quality of life for millions of individuals. Supported by clinical studies and FDA approval, Quell is a game-changer in the pain management space.
In addition to Quell, NeuroMetrix has a diverse portfolio of products designed to address various neurological conditions. These include the DPNCheck, a nerve conduction test that aids in the early detection of diabetic peripheral neuropathy, and the SENSUS Pain Management System, a non-invasive treatment option for chronic pain. These products demonstrate NeuroMetrix's commitment to providing innovative solutions for patients and healthcare professionals alike.
Sector
Healthcare
Industry
Medical Devices
CEO
Dr. Shai N. Gozani M.D., Ph.D.
Headquarters
Woburn
Employees
27
Exchange
NASDAQ
add NeuroMetrix  to watchlist

Keep an eye on NeuroMetrix

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is NeuroMetrix 's (NURO) price per share?
The current price per share for NeuroMetrix (NURO) is $3.7. The stock has seen a price change of -$0.01 recently, indicating a -0.27% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for NeuroMetrix (NURO)?
For NeuroMetrix (NURO), the 52-week high is $7.84, which is 111.89% from the current price. The 52-week low is $0.45, the current price is 722.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is NeuroMetrix (NURO) a growth stock?
NeuroMetrix (NURO) has shown an average price growth of 0.41% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NeuroMetrix as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is NeuroMetrix (NURO) stock price performance year to date (YTD)?
As of the latest data, NeuroMetrix (NURO) has a year-to-date price change of 7.47%. Over the past month, the stock has experienced a price change of -0%. Over the last three months, the change has been -16.67%. Over the past six months, the figure is 20.52%. Looking at a longer horizon, the five-year price change stands at -87.43%.
help
Is NeuroMetrix (NURO) a profitable company?
NeuroMetrix (NURO) has a net income of -$6.53M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 66.89% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -244.48% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $5.9M, although specific revenue growth data is currently not available. The gross profit is $3.95M. Operating income is noted at -$7.15M. Furthermore, the EBITDA is -$8.04M.
help
What is the market capitalization of NeuroMetrix (NURO)?
NeuroMetrix (NURO) has a market capitalization of $7.16M. The average daily trading volume is 7.03K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics, Inc. All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media